

Experimental adaptation of dengue virus 1 to *Aedes albopictus* mosquitoes by *in vivo* selection

Rachel Bellone^{1,2,£}, Sebastian Lequime,^{2,3,4,£} Henri Jupille,^{1,£} Giel P. Göertz,⁵ Fabien Aubry,³ Laurence Mousson,¹ Géraldine Piorkowski,^{6,7} Pei-Shi Yen,¹ Gaëlle Gabiane,¹ Marie Vazeille,¹ Anavaj Sakuntabhai,⁸ Gorben P. Pijlman,⁵ Xavier de Lamballerie,^{6,7} Louis Lambrechts,^{3,#} Anna-Bella Failloux^{1,#,*}

¹Department of Virology, Institut Pasteur, Arboviruses and Insect Vectors Unit, Paris, France;

²Sorbonne Université, Collège Doctoral, F75005 Paris, France ; ³Department of Virology,

Institut Pasteur, Insect-Virus Interactions Unit, CNRS UMR2000, Paris, France; ⁴Department

of Microbiology and Immunology, Rega Institute, KU Leuven-University of Leuven, Leuven,

Belgium; ⁵Laboratory of Virology, Wageningen University, Wageningen, The Netherlands;

⁶Aix Marseille University, IRD French Institute of Research for Development, EHESP French

School of Public Health, EPV UMR_D 190 ‘Emergence des Pathologies Virales’, Marseille,

France; ⁷IHU Méditerranée Infection, APHM Public Hospitals of Marseille, Marseille,

France; ⁸Department of Global Health, Institut Pasteur, Functional Genetics of Infectious

Diseases Unit, Paris, France.

[£]These authors contributed equally to this work.

[#]These authors contributed equally to this work.

*Correspondence: anna-bella.failloux@pasteur.fr

22 Abstract

23 In most of the world, Dengue virus (DENV) is mainly transmitted by the mosquito *Aedes*
 24 *aegypti* while in Europe, *Aedes albopictus* is responsible for human DENV cases since 2010.
 25 Identifying mutations that make DENV more competent for transmission by *Ae. albopictus*
 26 will help to predict emergence of epidemic strains. Ten serial passages *in vivo* in *Ae.*
 27 *albopictus* led to select DENV-1 strains with greater infectivity for this vector *in vivo* and in
 28 cultured mosquito cells. These changes were mediated by multiple adaptive mutations in the
 29 virus genome, including a mutation at position 10,418 in the DENV 3'UTR within an RNA
 30 stem-loop structure involved in subgenomic flavivirus RNA (sfRNA) production. Using
 31 reverse genetics, we showed that the 10,418 mutation alone does not confer a detectable
 32 increase in transmission efficiency *in vivo*. These results reveal the complex adaptive
 33 landscape of DENV transmission by mosquitoes and emphasize the role of epistasis in
 34 shaping evolutionary trajectories of DENV variants.

35
 36 **Keywords:** Vector-borne diseases, Europe, Emergence, Invasive species, Dengue, *Ae.*
 37 *albopictus*, adaptive-evolution, sfRNA

38

39

40 Introduction

41 Vector-borne diseases represent almost one fourth of all emerging infectious diseases
 42 worldwide (1). Among the emerging diseases, arboviruses occupy the top stair with several
 43 million human cases reported annually (2). Dengue virus (DENV) belongs to the *Flavivirus*
 44 genus of the *Flaviviridae* family and is by far the most important arboviral disease, with the
 45 number of human dengue infection cases exceeding 300 million annually; 96 million are
 46 symptomatic dengue fever/hemorrhagic fever leading to an estimated 22,000 human deaths
 47 (3). DENV is comprised of four antigenically distinct but genetically related serotypes
 48 referred to as DENV1-4 (4). Clinical manifestations range from mild cases of dengue fever to
 49 severe cases of dengue hemorrhagic fever and/or dengue shock syndrome. All four DENV
 50 serotypes are now circulating in Asia, Africa and America (5). In past centuries, dengue was
 51 not an uncommon disease in Europe: the last record of a dengue outbreak in the 20th century
 52 was in Athens, Greece, in 1927–1928 (6). This outbreak was unusual by the number of cases
 53 (~1 million) and the importance of severe clinical symptoms (e.g. hemorrhagic
 54 manifestations) leading to deaths (~1,000). After this Greek episode, dengue disappeared
 55 from Europe (7) as the mosquito *Aedes aegypti* disappeared from Eastern Mediterranean after
 56 1935 through improving sanitation and mosquito control measures (8). No local transmission
 57 of DENV has been reported in Europe until 2010, when clusters of autochthonous cases were
 58 reported in Southern France (9) and Croatia (10). In France, several transmission episodes
 59 were successively reported: 2013-2015 (11-13), 2018-2019 (14, 15). The vector was *Aedes*
 60 *albopictus*, first detected in Europe in 1979 in Albania (16), then in 1990 in Italy (17), and
 61 today, established in more than 20 European countries (18). Unexpectedly, *Ae. albopictus*
 62 from France was shown to be more competent to experimentally transmit DENV-1 strains
 63 compared to its counterpart *Ae. aegypti* from the French West Indies (19). Contrary to *Ae.*
 64 *aegypti*, the mosquito *Ae. albopictus* which is native to South-East Asia, has a broader range
 65 of hosts (20). When *Ae. aegypti* is absent, *Ae. albopictus* can be responsible for DENV

epidemics, as shown for the outbreaks in the Seychelles islands (21), Japan (22), La Réunion Island (23), and Hawaii (24). However, to date, *Ae. albopictus* is considered a minor vector of DENV relative to *Ae. aegypti* (25).

DENV serotypes have caused recent epidemics by changing their host ranges to increase infections in humans (26). As most arboviruses, DENV is capable of rapidly adapting to changes in their environment (or novel hosts) due to the accumulation of one or more specific mutations in the viral genome. For DENV, mutations in the 3' untranslated region (UTR) have previously been linked to increased epidemiological fitness of the virus via a mechanism involving increased expression of 3' UTR-derived subgenomic flavivirus RNA (sfRNA) expression (27). SfRNA is a known determinant for mosquito transmission of multiple flaviviruses like DENV, Zika virus and West Nile virus (28-32). Nucleotide substitutions in the 3'UTR reducing or ablating sfRNA expression negatively impact viral infection and transmission rates, suggesting that there is evolutionary pressure on conservation of RNA structures that dictate sfRNA expression in mosquitoes (33, 34). These studies indicate that subtle changes in the viral nucleotide composition can enhance the viral epidemic potential. On the same line, CHIKV has acquired the ability to spread globally owing to a single *Ae. albopictus*-adaptive mutation E1-226V (35). This mutation increased the infectivity of CHIKV in *Ae. albopictus* (36, 37).

We hypothesize that DENV can be selected for enhanced transmission by European *Ae. albopictus*, which would provide insight into future epidemic DENV strains that could pose a threat to human health. We conducted an experimental evolution study to identify nucleotide changes in the DENV genome by serially passaging DENV-1 isolates from Thailand (30A) and France (1806) in an *Ae. albopictus* population from Nice, France. Ten total passages were completed after which viral isolates were deep sequenced to identify newly acquired mutations. Importantly, we investigated whether the adaptation to the mosquito vector resulted in enhanced transmission potential or replication rate in mosquitoes. These results

exemplify the potential of virus-adaptation studies for the identification of DENV strains likely to emerge.

Results

European *Ae. albopictus* are differentially susceptible to DENV-1.

Arboviral transmission requires competent mosquitoes. To test whether European populations of *Ae. albopictus* can sustain local transmission of DENV-1, as reported in France (9) and Croatia (10), *Ae. albopictus* mosquitoes from Alessandria and Genoa (Italy), Cornelia and Martorell (Spain), Nice and Saint-Raphael (France) were experimentally infected with DENV-1 1806 from France or with DENV-1 30A from Thailand. Only engorged females were kept for analysis (samples size indicated in Fig. 1). When examining viral infection rate (Fig. 1a) and dissemination efficiency (Fig. 1b) at 14 and 21 days post-infection (dpi), percentages increased along with the dpi for the majority of virus/mosquito combinations. Within a mosquito population, the viral strain did not play a major role in either infection rate or dissemination efficiency (Fisher's exact test: $p > 0.05$ after Bonferroni correction; Table S1). In contrast, we observed significant differences between mosquito populations (Fisher's exact test: $p < 0.05$; Table S2) meaning that the geographic origin of the mosquito population is a critical factor that determines the outcome of viral infection and dissemination. Viral loads in heads (indicative of a successful dissemination from the midgut) did not mostly differ among mosquitoes having disseminated the virus (Fig. 1c, Table S3) (Wilcoxon Rank-Sum test: $p > 0.05$). No viral particles were detected in mosquito saliva (data not shown).

Experimental adaptation of DENV-1 to *Ae. albopictus*.

To examine whether DENV-1 can adapt to *Ae. albopictus*, DENV-1 1806 and DENV-1 30A were passaged 10 times in duplicate in *Ae. albopictus* mosquitoes from Nice, France (Fig. 2). Viral titers of cell culture supernatants collected at each passage fluctuated slightly from

passages 1 to 10 (Fig. S1). Additionally, the viruses were passaged 10 times in duplicate in *Ae. albopictus* C6/36 cells as a cell culture control. Full viral genomes were examined by deep sequencing at each passage (1-10) for the two replicates (R1 and R2) of *in vivo* mosquito infections and for passages 0 (parental strain), 1, 5 and 10 for the C6/36 cell culture control.

The two parental DENV-1 strains, 1806 and 30A, yielded a mean sequencing depth of 68,687X (1806) and 133,941X (30A), covering 99.97% and 100% of the reference genome at >100X. With the exception of 30A (passage 4, R2 in mosquitoes; covering only 34.62% of the reference genome at >100X), all passages had a mean coverage between 995X and 211,830X, paving between 100 and 99.25% of the reference genome at >100X (Fig. S2).

No major changes in single nucleotide variants (SNV) frequencies were detected when DENV-1 isolate was serially passaged on C6/36 cells (Fig. 3a). Remarkably, we did not detect a single mutation that reached consensus level (frequency >50%) in the C6/36 control passages. In contrast, when DENV-1 1806 or 30A was passaged in *Ae. albopictus* mosquitoes, consensus level variants were detected as soon as passages 2 (DENV-1 1806) and 5 (DENV-1 30A), and a total of 30 consensus level variants were detected at passage 10 (Fig. 3a, Table S4). In total, twenty consensus level SNVs were detected in DENV-1 30A (positions 448, 694, 1611, 1768, 1959, 2002, 2200, 2716, 2977, 3442, 5822, 6658, 6728, 7267, 7952, 8149, 8485, 9504, 10208, 10258) and 10 in DENV-1 1806 (positions 1840, 2719, 3001, 3757, 4552, 4606, 5667, 7360, 9067, 10418). Out of the 30 consensus variants, 23 synonymous changes, 6 non-synonymous and one variant located in the 3'UTR were detected (Fig. 3b). The variant located at position 10,418 in the 3'UTR was the only SNV shared between the replicates R1 and R2 of DENV-1 1806. Its frequency increased over the passages, reaching consensus level at passage 4 for replicate 1 and passage 8 for replicate 2 (Fig. 3a). The variant became almost fixed (frequency > 99%) at passage 5 for replicate 1 and passage 10 in replicate 2. No SNV was common to the two replicates for DENV-1 30A. These results indicate that DENV-1 accumulates mutations during passaging in *Ae. albopictus*

that likely facilitate virus replication in the mosquito or virus dissemination into the saliva to facilitate transmission.

***Ae. albopictus* adapted DENV-1 1806 has an increased transmission rate in *Ae. albopictus*.**

To investigate whether the mosquito adapted DENV-1 1806 has increased transmission potential as compared to the parental isolate, *Ae. aegypti* Pazar (Turkey) and *Ae. albopictus* Nice (France) were provided with an infectious blood-meal containing 10⁷ FFU/mL DENV-1 1806 parental, or replicate of the mosquito passaged virus (R1 and R2). Viral infection rates were high (>40%) and higher for the P10 viruses in *Ae. albopictus* at 21 dpi (Fig. 4a-b). Viral dissemination was lower at early dpi but remained high at 21 dpi in both mosquito species with a higher dissemination of P10 viruses compared to the parental virus (Fig. 4c-d). Transmission was surprisingly low in *Ae. aegypti* (Fig. 4E) compared to *Ae. albopictus* (Fig. 4f) suggesting a stronger effect of salivary glands as a barrier to virus release in saliva of *Ae. aegypti*. At 21 dpi, the two P10 viruses had higher infection rates (Fig. 4b), higher dissemination rates (Fig. 4d) and higher transmission rates (~2.5 fold) in *Ae. albopictus* than their parental strain (Fisher's exact test: $p < 10^{-4}$; IR, $p = 0.0001$; DE, $p = 0.0001$; TE, $p = 0.022$). Collectively, these results indicate that the accumulation of adaptive mutations during passaging in *Ae. albopictus* for the P10_R1 and P10_R2 viruses is beneficial for virus infection, dissemination and thus transmission by *Ae. albopictus* mosquitoes.

***Ae. albopictus* adapted DENV-1 1806 has a replicative advantage in RNAi-competent and -deficient mosquito cells.**

To determine whether the adaptive mutations in DENV-1 1806 after serial passaging in *Ae. albopictus* mosquitoes were causing a replicative advantage, we examined the replication kinetics of DENV-1 1806 parental, R1 and R2 in *Ae. albopictus* C6/36 (RNAi-deficient) and

U4.4 (RNAi-competent) cells (Fig. 5a-b) compared to kinetics in HFF cells (Fig. 5c). In C6/36 cells, the parental virus reached slightly lower titers at 6, 24 and 48 hours post-infection (hpi) as compared to the mosquito passaged R1/R2 viruses (Fig. 5a). The mosquito adapted R1/R2 viruses presented a significant increase in viral titer at 24 hpi (R1 (mean $\pm$ SD): Log_{10} 4.42 ± 0.10 ; R2: Log_{10} 4.68 ± 0.14) compared to the parental strain (Log_{10} 3.31 ± 0.15) (χ^2 test: $p = 0.027$). In U4.4 cells, the same trend was observed (Fig. 5b) with a lower titer at 24 hpi for the parental strain (Log_{10} 2.84 ± 0.06) as opposed to the two P10 viruses (R1: Log_{10} 4.19 ± 0.29 ; R2: Log_{10} 4.47 ± 0.03). In human cells (Fig. 5c), viral titers remained between 2 and 3 Log_{10} from 0 to 72 hpi. These results indicate that the adaptive mutations after serial passaging of DENV-1 1806 in *Ae. albopictus* mosquitoes increase the replication rate in mosquito cells and a disadvantage in human cells.

Vizualisation of substitutions in 3'UTR of DENV-1 1806 on RNA stem-loop structures.

The highly structured flavivirus 3'UTR is important for virus replication, genome translation and production of non-coding sfRNA (38). sfRNA is formed as a result of incomplete degradation of the viral genomic RNA by the 5'-3' exoribonuclease XRN1, which stalls on stem loop (SL) and dumbbell (DB) RNA structures in the 3'UTR (38, 39). It has been shown that passaging DENV on mosquito cells can result in high mutation rates in the 3'UTR and might alter the abundance of sfRNA during infection (33, 40). The largest sfRNA species, sfRNA1, determines pathogenicity (41), inhibits host innate immunity (27, 42) and is essential for efficient transmission of flaviviruses by mosquitoes (28-32, 43, 44). We therefore investigated if the consensus level mutation 10,418 that occurred in the 3'UTR after passaging could lead to changes in the 3'UTR secondary RNA structures and subsequent sfRNA formation. Mutations with an SNV frequency ≥ 0.05 only occurred in the SL-II and 3'SL structures (Fig. 6a; red nucleotides). When examining mutations in the 3'SL, the same SNVs were found in the two parental strains and the passages 10 indicating that those

mutations were already present in the initial viral populations and were not selected consequently to serial passages in mosquitoes (Fig. 6b). We observed that the mosquito passaged DENV-1 1806 presented a U→C substitution at position 10,418 on the top of SL-II, which was not observed for DENV-1 30A. SL-II is the XRN1 stalling structure required for sfRNA2 formation, which requires the presence of a RNA pseudoknot interaction and a complex tertiary folding (45) (Fig. 6b). Pseudoknot formation and other known tertiary RNA interactions are not expected to be directly disrupted due to the 10,4018 sequence change (Fig. 6b). However, the U→C mutation may indirectly affect the 3D folding of the stem loop. Passages on C6/36 cells also gave rise to lower-frequency mutations in SL-II (frequency < 0.2), but none of them reached consensus level.

Increased transmission potential of *Ae. albopictus*-adapted DENV-1 is not associated with significantly increased sfRNA production.

As sfRNAs are generated due to stalling of XRN1 on RNA secondary structures in the viral 3'UTR (41), sequence changes in the 3'UTR, in particular those that occur in RNA structures involved in XRN1 stalling, may affect the length and expression level of sfRNAs. To investigate whether the production of sfRNA is affected by the mutation 10,418 in DENV-1 1806 R1/R2, a Northern blot analysis was performed using a 3'UTR specific probe on total RNA extracted from U4.4 cells infected with DENV-1 1806 parental, R1 or R2 (Fig. 7). Viral gRNA and abundant sfRNA1 were produced by both the parental and R1/R2 viruses (Fig. 7a). The quantity of sfRNA1 was visually similar across all samples on the gel, although ImageJ quantification of the band intensities revealed that the ratio of sfRNA/gRNA was ~1.5 fold higher in R1 and R2 samples as compared to the parental samples (Fig. 7b). Minimal amounts of smaller sfRNA species (i.e. sfRNA2, 3, 4) were observed, indicating that DENV-1 predominantly produces sfRNA1 during infection of mosquito cells. These results show that

the increased transmission potential of the *Ae. albopictus* adapted DENV-1 1806 is unlikely to be caused by differences in sfRNA production.

The 10,418 mutation alone does not significantly enhance DENV-1 transmission by *Ae. albopictus*

To test whether the U→C substitution at position 10,418 alone would recapitulate the observed phenotype in *Ae. albopictus*, three reverse genetic constructs (Parental construct, P10 construct 1 and P10 construct 2) were produced using the ISA method and then sequenced. As expected, the two P10 constructs presented the 10,418 mutation at a frequency close to 100% (Table S5). The genetic constructs also displayed other SNVs at frequencies higher than 5% but none of them reached consensus level with the exception of one SNV with 52.5% frequency in P10 construct 1 (5173/nsp3) and two SNVs close to fixation in P10 construct 2 (7321/nsp4b and 9571/nsp5).

Twenty-one days after an infectious blood meal containing the reverse genetic constructs, *Ae. albopictus* Nice mosquitoes were examined for transmission by analyzing viral particles in their saliva. When estimating the transmission efficiency, no significant differences were detected when comparing the five viral strains, the reverse genetic constructs in reference to the template (Parental, P10) and the two P10 constructs (1 and 2) (Fisher's exact test: $p > 0.05$) (Fig. 8a). Similarly, when examining the number of viral particles in individual mosquito saliva, no statistical significance was found whatever the comparison (Wilcoxon Rank-Sum test: $p > 0.05$) (Fig. 8b).

To confirm the profile of P10 construct 1, we performed a replicate using the same experimental design. TE (Fig. 8c) and the viral load in saliva (Fig. 8d) were determined. We found that the replicate 2 shares the same profile than the replicate 1 (Fig. 8a, 8b). Altogether, these results indicate that the mutation 10,418 alone does not enhance transmission of DENV-1 in *Ae. albopictus*.

247

248 Discussion

249 In this study, we developed an experimental evolution approach to enhance the transmission
 250 of DENV-1 by the vector *Ae. albopictus*. A number of conserved nucleotide variants were
 251 observed in all mosquito-passaged DENV-1 viruses, but not in the viruses passaged in
 252 mosquito cells, indicating that DENV-1 virus adapts specifically to cope with the adaptive
 253 pressure in the mosquito. A nucleotide change at position 10,418 in the 3'UTR was observed
 254 in both replicates of the *Ae. albopictus* adapted DENV-1 1806. Independent fixation of the
 255 mutation in two replicates with a sharp rise in frequency is consistent with adaptive evolution.
 256 Importantly, the *Ae. albopictus* adapted isolates displayed higher DENV-1 infection,
 257 dissemination and transmission efficiencies in *Ae. albopictus*. Our results show that we have
 258 successfully adapted DENV-1 to *Ae. albopictus*, through selection of adaptive mutations
 259 including the 10,418 mutation in the 3'UTR of the viral genome by sequential passaging *in*
 260 *vivo*.

261 *Ae. albopictus* usually acts as a secondary vector of DENV (20), but in the absence of
 262 *Ae. aegypti*, it can act as the main vector in some regions including Europe (9-13). First
 263 detected in Albania in 1979 (16), *Ae. albopictus* is now present in more than 20 European
 264 countries (18). We showed that *Ae. albopictus* from France, Italy and Spain were susceptible
 265 to infection by DENV-1 (Fig. 1), indicating that *Ae. albopictus* is indeed a vector species for
 266 DENV in Europe. The main sources of introductions in Europe were mosquitoes from Italy,
 267 which were previously imported from North America (46). Recurrent introduction events
 268 have contributed to increase the genetic diversity of European *Ae. albopictus* populations
 269 (47), an important factor shaping vector competence (25).

270 Here, we experimentally selected DENV-1 isolates for enhanced transmission by *Ae.*
 271 *albopictus*. Our experimental procedure was designed to accelerate the selection process of
 272 DENV-1 by serial passages in *Ae. albopictus* mosquitoes without alternation in the

mammalian host. After 10 passages in *Ae. albopictus* collected in Nice, France, we successfully adapted DENV-1 1806 and DENV-1 30A to *Ae. albopictus* through the accumulation of adaptive mutations across the genome, although only a single mutation was fixed in both replicates for the 1806 isolate. Importantly, for DENV-1 1806, these adaptive mutations increased the infection, dissemination and transmission rates of DENV-1 by *Ae. albopictus* (Fig. 4). Furthermore, growth kinetics of the DENV-1 1806 viruses were increased in both RNAi-competent U4.4 and RNAi-deficient C6/36 cells, indicating that the mutations cause an increase in viral replicative fitness in cell cultures regardless of a functional RNAi machinery (Fig. 5). These mosquito-selected viral variants were less adapted to replicate on mammalian cells (48). In a similar approach, Stapleford et al. (2014) succeeded in monitoring the selection of epidemic variants of CHIKV adapted to *Ae. albopictus* consolidating the idea that *in vivo* approaches can contribute in predicting new variants able to emerge and displace currently circulating viral strains (49).

We identified a mutation that was fixed in both replicates of the mosquito passaged DENV-1806 isolate, suggesting that this residue is involved in the adaptive-evolution that results in the increased transmission and replication potential of the virus. This shared substitution was located at position 10,418 in the highly structured 3'UTR of the DENV-1 genome. Specifically, the mutation was present in the SL-II RNA structure (Fig. 6); which is required for the production of sfRNA2 (41). XRN1 stalls at SL and dumbbell (DB) RNA structures within the 3'UTR, which results in accumulating sfRNAs of different sizes (41, 50). The stalling of XRN1 occurs due to steric hindrance caused by interactions of pseudoknots (PK) and other tertiary RNA structures (45, 51). Prediction of RNA structures involved in XRN1 stalling (the so-called xrRNAs) with Mfold has proven to be an useful starting point but undeniably has limitations, e.g. pseudoknots cannot be predicted and 3D RNA folding is not taken into account. Although Mfold predictions and visual pseudoknot mapping have helped to elucidate mechanisms of XRN1 stalling (41, 45, 50), the exact

structural basis for XRN1 stalling, the involvement of a unique three-way junction and internal tertiary interactions were only revealed by determining the crystal structure of several xrRNAs (52, 53). In mammalian cells, sfRNA is essential for inducing pathogenicity (41), and acts as an antagonist of innate immune responses (27, 42). In mosquito cells, sfRNA has been reported as an antagonist of the RNAi response *in vitro* (54, 55) and contributes to enhance the *in vivo* infection of mosquitoes and further dissemination from the midgut into the haemocoel (32) and subsequent salivary gland infection (44). Villordo et al. (2015) previously demonstrated that when passaging DENV-2 20 times in C6/36 mosquito cells, SL-II is highly mutated while the upstream SL-I mutates mostly upon passaging in mammalian cells (40). The mutations in SL-II were shown to increase DENV-2 replication in mosquito cells (40). The mutation that we found at the position 10,418 in SL-II is in line with these findings, supporting the mutation pressure on SL-II *in vivo*, although we did not observe significant mutations during passaging in C6/36 cells.

For DENV-2, it has been shown that during replication in human cells, mainly sfRNA1 is produced, while mosquito-adapted DENV-2 accumulates more abundant sfRNA3 and sfRNA4 (33). We show that DENV-1 1806 produced abundant sfRNA1 while quantities of sfRNA2,3 and possibly sfRNA4 were below the detection limit (Fig. 7), suggesting possible differences in the production of sfRNA species between DENV-1 and DENV-2. Despite the presence of the 10,418 mutation, the *Ae. albopictus* adapted DENV-1 1806 did not show a significantly altered production of sfRNA species. Although we cannot exclude an effect on cellular binding partners that might require an intact 3'UTR for their interaction with the viral genome (38), it is unlikely that sfRNAs were a primary driver of DENV-1 adaptation to *Ae. albopictus*.

We used reverse genetics to evaluate the effect of the 10,418 mutation on DENV-1 transmission by *Ae. albopictus* mosquitoes *in vivo*, but our results did not provide experimental support for a phenotypic effect of the 10,418 mutation alone. For two different

genetic constructs harboring the 10,418 mutation (together with different adventitious mutations), there was no detectable difference in transmission efficiency. Introducing the 10,418 did not recapitulate the adapted phenotype of the P10 viruses and points to a more complex adaptive landscape than a single-mutation effect. Because our genetic constructs focused on the 10,418 mutation did not include other mutations present in the P10 viruses, it implies that the enhanced transmission phenotype reflected the combined effect of several mutations. Such epistatic relationships have been documented to shape the adaptive landscapes of CHIKV (56, 57) and more recently DENV (58). Interestingly, the 10,418 mutation was the only shared mutation among replicates of adapted viruses (Fig. 3), indicating that DENV-1 adaptation to *Ae. albopictus* can result from distinct evolutionary trajectories involving different sets of mutations.

Our experimental approach has succeeded in enhancing the transmission of DENV-1 by multiple passages in the *Ae. albopictus* vector. This protocol can be extended to other arboviruses and vector species, and contribute to predict future epidemic variants. Together, this may ultimately lead to new insights into the mechanisms of arbovirus transmission by mosquitoes.

Materials and Methods

Ethics statement

The Institut Pasteur animal facility has received accreditation from the French Ministry of Agriculture to perform experiments on live animals in compliance with the French and European regulations on care and protection of laboratory animals (EC Directive 2010/63, French Law 2013-118, February 6th, 2013). This study was approved by the Ethics Committee #89 and registered under the reference APAFIS#6573-2016061412077987 v2. Mice were only used for mosquito rearing as a blood source, according to approved protocol.

Cell cultures

Ae. albopictus C6/36 cells were maintained at 28°C in Leibovitz L-15 medium supplemented with non-essential amino-acids (NEAA) (1X), 10% fetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/mL streptomycin. These cells are defective in typical siRNAs, the hallmark of exogenous RNAi mediated antiviral immunity (59). *Ae. albopictus* U4.4 cells were maintained in L-15 medium supplemented with non-essential amino-acids (1X), 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin at 28°C. HFF (Human Foreskin Fibroblast) cells were maintained at 37°C, 5% CO₂ in Dulbecco's Modified Eagle medium (DMEM) supplemented with pyruvate, 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin. The human embryonic kidney HEK-293 cells (ATCC number CCL-1573) were grown at 37°C with 5% CO₂ in tissue-culture flasks with vented caps, in a minimal essential medium (MEM, Life Technologies) supplemented with 7% FBS, 1% PS and 1X NEAA.

Viruses

We used two DENV-1 strains isolated from DF cases: DENV-1 1806 from an autochthonous case from Nice, France in 2010 (provided by the National Reference Center of Arboviruses, France) and DENV-1 30A from a patient in Kamphaeng Phet, Thailand in 2010 (provided by the Afrims, Thailand and under accession number HG316482 in GenBank). The 2nd passage of DENV-1 1806 on African green monkey kidney Vero cells (60) and the 2nd passage of DENV-1 30A on C6/36 *Ae. albopictus* cells (61) were used for mosquito infections. Serial dilutions were used to determine the titer of viral stocks that was expressed in focus-forming units (FFU)/mL.

Mosquito strains

Six populations of *Ae. albopictus* have been established from eggs: Genoa (Italy), Alessandria (Italy), Cornella (Spain), Martorell (Spain), Nice Jean Archet (France), and Saint-Raphael

(France) (Table 1). They were tested to appraise vector competence to DENV-1 isolates. Together with *Ae. albopictus* Nice Jean Archet (France), *Ae. aegypti* Pazar (Turkey) was utilized to compare vector competence using viruses isolated after 10 passages on *Ae. albopictus*. Eggs were collected from ovitraps and sent to the Institut Pasteur in Paris, where they were reared in standardized conditions. After hatching, larvae were distributed in pans containing a yeast tablet renewed as needed in 1 L of tap water. Adults were placed in cages maintained at $28\pm1^{\circ}\text{C}$, at relative humidity of 80% and a light:dark cycle of 16h:8h, with free access to 10% sucrose solution. Oral infection experiments were performed using mosquitoes from the F2-F11 generations. Owing to the limited number of mosquitoes, only one biological replicate was performed for each pairing population-virus.

Mosquito infections

One-week-old females were starved 24 hrs prior an infectious blood-meal in a BSL-3 laboratory. Five batches of 60 mosquito females were then allowed to feed for 15 min through a piece of pork intestine covering the base of a Hemotek feeder containing the infectious blood-meal maintained at 37°C . Only engorged females were kept and incubated under controlled conditions ($28\pm1^{\circ}\text{C}$, relative humidity of 80%, light:dark cycle of 16h:8h).

For vector competence assays

Fourteen and 21 days after an infectious blood-meal provided at a titer of 10^7 FFU/mL, vector competence was assessed based on two phenotypes: (i) viral infection of mosquito and (ii) viral dissemination from the midgut into mosquito general cavity. Infection rate (IR) was determined as the proportion of mosquitoes with infected midgut and dissemination efficiency (DE) was defined as the percentage of mosquitoes with virus detected in heads suggesting a successful viral dissemination from the midgut. IR and DE were calculated by titrating body and head homogenates.

For serial passages

As the first autochthonous DENV cases were reported in Nice in 2010 (9), *Ae. albopictus* isolated in Nice was used to achieve the experimental selection of DENV-1 isolates (Fig. 2). Mosquitoes were orally infected with DENV-1 supernatant provided in a blood-meal at a final titer of $10^{6.5}$ FFU/mL using the hemotek system. Engorged mosquitoes were incubated at 28°C for 19-21 days and then processed for saliva collection. 15-25 saliva were pooled and the volume of the pool was adjusted to 600 µL with DMEM prior to filtration through a Millipore H membrane (0.22 µm). An aliquot of 300 µL of each sample was used to inoculate a sub-confluent flask (25 cm²) of C6/36 *Ae. albopictus* cells. After 1 hr, the inoculum was discarded and cells were rinsed once with medium. Five mL of DMEM medium complemented with 2% FBS was added and cells were incubated for 8 days at 28°C. Cell culture supernatants were then collected and provided to mosquitoes to run the next passage. Passages P1 to P3 were performed with mosquitoes of the F3 generation and passages P4 to P10 with mosquitoes of the F4 generation. C6/36 supernatants collected at each passage were used undiluted for the next mosquito blood-meal. Ten passages were performed. Control isolates corresponded to serially passaged viruses on C6/36 cells to identify mutations resulting from genetic drift or adaptation to insect cell line; 500 µL of the previous passage were used to inoculate the next flask of C6/36 cells. Two biological replicates R1 and R2 were performed to test the variability between samples submitted to the same protocol of selection. Vector competence using the parental and P10 isolates was assessed by calculating: (i) infection rate (IR, proportion of mosquitoes with infected midgut), (ii) dissemination efficiency (DE, proportion of mosquitoes able to disseminate the virus from the midgut among tested mosquitoes), and (iii) transmission efficiency (TE, proportion of mosquitoes with the virus detected in saliva among tested mosquitoes).

Virus deep sequencing

Total RNA was extracted from cell culture supernatant using QIAamp Viral RNA Mini Kit (Qiagen, Germany) and DNase treated (Turbo DNase, Life Technologies, USA). Following purification with magnetic beads (Agencourt RNAClean XP, Beckman Coulter, California, USA), RNA was reverse transcribed using Transcriptor High Fidelity cDNA Synthesis Kit and a specific 3'-UTR DENV-1 primer (Roche Applied Science, Mannheim, Germany), d1a5B 5'-AGAACCTGTTGATTCAACRGC-3' (62). Second strand was then synthesized in a unique reaction with *E. coli* DNA ligase (New England Biolabs, Massachusetts, USA), *E. coli* DNA polymerase I (New England Biolabs), *E. coli* RNase H (New England Biolabs) in second strand synthesis buffer (New England Biolabs). After purification with magnetic beads (Agencourt AMPure XP, Beckman Coulter), dsDNA was quantified with fluorometric method (Quant-iT PicoGreen dsDNA, Invitrogen, Massachusetts, USA).

Sequencing libraries were prepared using Nextera XT DNA Library Preparation Kit (Illumina, San Diego, USA), multiplexed and sequenced in single end in two independent runs on an Illumina NextSeq 500 platform using a mid-output 150-cycle v2 kit (Illumina). Reads were trimmed (Trimmomatic v0.33) (63) after demultiplexing (bcl2fastq v.2.15.0, Illumina) to remove adaptor sequences, and reads shorter than 32 nucleotides were discarded. Full-length genome of the DENV-1 1806 was assembled *de novo* using Ray v2.0.0 (64) with the original stock sample. The newly assembled DENV genome contig was extended in 3' and 5' using closest BLAST hit full DENV-1 genome (accession number EU482591). This chimeric construct was used to map reads used for assembly using Bowtie 2 v2.1.0 (65). Alignment file was converted, sorted and indexed using Samtools v0.1.19 (66). Coverage and sequencing depth were assessed using bedtools v2.17.0 (67). Single nucleotide variants and their frequency were called using LoFreq* v2.1.1 (68) and used to correct the chimeric construct. Only nucleotides with >10X coverage were conserved for generating the consensus sequence. A final full-length genome sequence for DENV-1 1806 strain was deposited to GenBank (accession number MG518567).

After quality control, reads from all samples were mapped to the newly assembled DENV-1 1806 strain genome sequence or previously sequenced reference genome KDH0030A (accession number HG316482) using Bowtie v2.1.0 (65). The alignment file was converted, sorted and indexed using Samtools v0.1.19 (66), and the coverage and sequencing depth were assessed for each sample using bedtools v2.17.0 (67). Single nucleotide variants (SNVs) and their frequency were then called using LoFreq* v2.1.1 (68), and their effect at the amino-acid level was assessed by SNPgenie v1.2 (69).

RNA structure modeling in silico

The Mfold Web server was used with standard settings and flat exterior loop type (70) to fold the secondary RNA structures, which were then visualized using the VARNA RNA editing package (71). Pseudoknot RNA interactions were drawn as previously described for DENV (45, 72). Mutation frequencies of individual nucleotides were determined by averaging the nucleotide allele frequency from the deep sequencing results of the duplicates per treatment.

Virus growth curves

To measure viral replicative fitness, growth curves were conducted in *Ae. albopictus* C6/36 and U4.4 mosquito cells, and Human Foreskin Fibroblasts (HFF) cells. Confluent cell monolayers were prepared and inoculated with viruses simultaneously in triplicates at a MOI of 0.1 PFU/cell. Cells were incubated for 1 hr in appropriate conditions and viral inoculum was removed to eliminate free virus. Five mL of medium supplemented with 2% FBS were then added and mosquito cells were incubated at 28°C (mosquito cells) or 37°C (human cells). At various times (4, 6, 8, 10, 24, 48 and 72 hrs) post-inoculation (pi), supernatants were collected and titrated by focus fluorescent assay on *Ae. albopictus* C6/36 cells. After incubation at 28°C for 5 days, plates were stained using hyper immune ascetic fluid specific to DENV as primary antibody (Millipore, Molsheim, France). A Fluorescein-conjugated goat

anti-mouse was used as the second antibody (Thermofisher). Three viral strains were used: the parental strain and two 10th passages, P10_R1 and P10_R2. Viral titer was expressed in FFU/mL. Three biological replicates were performed for each cell-virus pairing.

RNA isolation and Northern blotting

Total RNA was isolated from cell monolayers using TRIzol reagent (Invitrogen, Massachusetts, France) following the manufacturer's protocol. Mosquito DENV-1 infected bodies were homogenized individually in 500 µL of Leibovitz L15 medium (Invitrogen) supplemented with 2% fetal bovine serum for 1 min at maximum speed. Homogenates were then filtered with a filter unit (0.22 µm) (Ultrafree® MC-GV, Merck, New Jersey, USA). Two samples of each filtrate were inoculated onto monolayers of *Ae. albopictus* C6/36 cell culture in 6-well plates. After incubation at 28°C for 6 days, samples were homogenized with 1 mL TRIzol reagent. RNA isolations were performed using the standard TRIzol protocol. Samples were eluted in 30 µL RNase-free Milli-Q water and stored at -80°C until further processing. A DENV-1 3'UTR specific probe was generated by PCR reaction with GoTaq Polymerase (Promega, Wisconsin, USA) containing DIG DNA-labelling mix (Roche) and primers DENV-1 3'UTR FW (AGTCAGGCCAGATTAAGCCATAGTACGG) and DENV-1 3'UTR RV (ATTCCATTTTCTGGCGTTCTGTGCCTGG) using cDNA from cells infected with DENV-1 1806 as a template. Five micrograms of total RNA was subjected to sRNA-optimized northern blot as has been described previously (32). Briefly, total RNA was denatured and size separated on 6% polyacrylamide–7 M urea–0.5× Tris-borate-EDTA (TBE) gel for 1.45 hrs at 150 V. The RNA was semi-dry-blotted on a Hybond-N membrane, UV cross-linked and pre-hybridized for 1 hr at 50°C in modified Church buffer containing 10% formamide. DENV-1 3'UTR specific Dig-labelled probe was denatured and blots were hybridized overnight at 50°C in modified church/10% formamide buffer containing 2 µL of DIG-labelled probe. Blots were developed with AP-labeled anti-DIG antibodies and NBT-

BCIP solution before observing the signal using a Bio-Rad Gel Doc scanner. Quantification of band signal intensities was performed in ImageJ by transforming the image to 8-bit format, inverting the image, and analyzing the band intensity using the measure function. The Ratio sfRNA/gRNA was calculated by dividing the intensity of the sfRNA by the intensity of the gRNA band for each sample, and then normalized to the average ratio of the parental samples.

ISA reverse genetics

The T>C mutation at position 10,418 identified at passage 10 was inserted into a DENV-1 1806 backbone using the ISA (Infectious Subgenomic Amplicons) reverse genetics method as previously described (73).

Preparation of subgenomic DNA fragments

The viral genome was amplified by RT-PCR from the DENV-1 1806 viral RNA as three overlapping DNA fragments. Two additional fragments were *de novo* synthesized (Genscript) and amplified by PCR (primers are listed in Table S6). The first primer consisted of the human cytomegalovirus promoter (pCMV) and the second primer of the last 367 nucleotides of the 3'UTR of the DENV-1 1806 with or without the 10,418 T>C mutation and the hepatitis delta ribozyme followed by the simian virus 40 polyadenylation signal (HDR/SV40pA) (sequences are listed in Supplemental Text). RT mixes were prepared using the superscript IV reverse transcriptase kit (Life Technologies, CA, USA) and PCR mixes using the Q5® High-Fidelity PCR Kit (New England Biolabs, MA, USA) following the manufacturer's instructions. RT were performed in the following conditions: 25°C for 10 min followed by 37°C for 50 min and 70°C 15 min. PCR amplifications were performed in the following conditions: 98°C for 30 sec followed by 35 cycles of 98°C for 10 s, 62°C for 30 s, 72°C for 2 min 30 s, with a 2 min final elongation at 72°C. PCR product sizes and quality were controlled by running gel electrophoresis and DNA fragments were purified using a QIAquick PCR Purification Kit (Qiagen, Hilden, Germany).

Cell transfection

HEK-293 cells were seeded into six-well cell culture plates one day prior to transfection. Cells were transfected with 2 µg of an equimolar mix of the five DNA fragments using lipofectamine 3000 (Life Technologies) following the manufacturer's instructions. Each transfection was performed in five replicates. After incubating for 24 hrs, the cell supernatant medium was removed and replaced by fresh cell culture medium. Seven days post-transfection, cell supernatant medium was passaged two times using six-well cell culture plates of confluent C6/36 cells. Cells were subsequently inoculated with 100 µL of diluted (1/3) cell supernatant media, incubated 1 hr, washed with PBS 1X, and incubated 7 days with 3 mL of medium. Remaining cell supernatant medium was stored at -80 °C. The second passage was used to produce virus stock solutions of DENV-1 1806 WT and mutant viruses. Transmission efficiency was assessed 21 days after an infectious blood meal containing the Parental, the Parental construct, the P10 strain, the P10 constructs (1 and 2) provided separately at a titer of 10^7 FFU/mL.

Statistical analyses

Statistical analyses were conducted using the STATA software (StataCorp LP, Texas, and USA). P-values > 0.05 were considered non-significant. If necessary, the significance level of each test was adjusted based on the number of tests run, according to the sequential method of Bonferroni (74).

Acknowledgments

The authors thank Pascal Delaunay (Centre Hospitalier Universitaire Nice, France), Ashgar Talbalaghi (Vector Control, Italy), Roger Eritja (Universitat de Barcelona, Spain), Vincent Robert (IRD, Montpellier) for providing mosquito eggs. This study was supported by a grant FP7-HEALTH HEALTH.2011.2.3.3-2 (grant number: 282378) "Dengue research Framework

for resisting epidemics in Europe” (DENFREE), the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant n°ANR-10-LABX-62-IBEID), the European Union's Horizon 2020 research and innovation programme under ZIKAlliance grant agreement No 734548 and the Institut Pasteur. PY was supported by the Pasteur-Paris University (PPU) program. LL received support from Agence Nationale de la Recherche (grant ANR-17-ERC2-0016-01), the City of Paris Emergence(s) program in Biomedical Research, and the European Union's Horizon 2020 research and innovation programme under ZikaPLAN grant agreement No 734584. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

LL and ABF designed the research. RB, SL, HJ, GPG, LM, GP, and FA performed experiments. LM, GP, PSY, GG, and MV provided reagents and analytical tools. AS and XDL provided expertise and feedback. RB, SL, HJ, GPG, GPP, and ABF analyzed the data. GPG, GPP, LL, and ABF wrote the manuscript. LL and ABF secure funding.

Declaration of interests

The authors declare no competing interests.

References

1. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. *Nature*. 2008;451(7181):990-3.
2. Liang G, Gao X, Gould EA. Factors responsible for the emergence of arboviruses; strategies, challenges and limitations for their control. *Emerg Microbes Infect*. 2015;4(3):e18.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504-7.
4. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. *J Gen Virol*. 1989;70 (Pt 1):37-43.

- 588 5. Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453-65.
- 589 6. Anon. The dengue epidemic in Greece. League Nations Monthly Epidemiol Rep. 1928;7:334.
- 590 7. Rezza G. Dengue and chikungunya: long-distance spread and outbreaks in naive areas.
- 591 Pathog Glob Health. 2014;108(8):349-55.
- 592 8. Curtin TJ. Status of *Aedes aegypti* in the Eastern Mediterranean. J Med Entomol.
- 593 1967;4(1):48-50.
- 594 9. La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, Despres P, et al. First two
- 595 autochthonous dengue virus infections in metropolitan France, September 2010. Euro surveillance :
- 596 bulletin Européen sur les maladies transmissibles = European communicable disease bulletin.
- 597 2010;15(39):19676.
- 598 10. Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Klobucar A, Pem-Novosel I, et al.
- 599 Autochthonous dengue fever in Croatia, August-September 2010. Euro surveillance : bulletin
- 600 Européen sur les maladies transmissibles = European communicable disease bulletin. 2011;16(9):pii:
- 601 19805.
- 602 11. Marchand E, Prat C, Jeannin C, Lafont E, Bergmann T, Flusin O, et al. Autochthonous case of
- 603 dengue in France, October 2013. Euro surveillance : bulletin Européen sur les maladies transmissibles
- 604 = European communicable disease bulletin. 2013;18(50):20661.
- 605 12. Giron S, Rizzi J, Leparç-Goffart I, Septfons A, Tine R, Cadiou B, et al. Nouvelles apparitions de
- 606 cas autochtones de dengue en région Provence-Alpes-Côte d'Azur, France, août-septembre 2014.
- 607 Bull Epidémiol Hebd. 2015;13-14:217-25.
- 608 13. Succo T, Leparç-Goffart I, Ferre JB, Roiz D, Broche B, Maquart M, et al. Autochthonous
- 609 dengue outbreak in Nîmes, South of France, July to September 2015. Euro surveillance : bulletin
- 610 Européen sur les maladies transmissibles = European communicable disease bulletin. 2016;21(21).
- 611 14. Franke F, Giron S, Cochet A, Jeannin C, Leparç-Goffart I, de Valk H, et al. Émergences de
- 612 dengue et de chikungunya en France métropolitaine, 2010-2018. Bull Epidémiol Hebd. 2019;19-
- 613 20:374-82.
- 614 15. France SP. 2019. Available from: [https://www.santepubliquefrance.fr/maladies-et-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-transmission-vectorielle/chikungunya/articles/donnees-en-france-metropolitaine/chikungunya-dengue-et-zika-donnees-de-la-surveillance-renforcee-en-france-metropolitaine-en-2019)
- 615 [traumatismes/maladies-a-transmission-vectorielle/chikungunya/articles/donnees-en-france-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-transmission-vectorielle/chikungunya/articles/donnees-en-france-metropolitaine/chikungunya-dengue-et-zika-donnees-de-la-surveillance-renforcee-en-france-metropolitaine-en-2019)
- 616 [metropolitaine/chikungunya-dengue-et-zika-donnees-de-la-surveillance-renforcee-en-france-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-transmission-vectorielle/chikungunya/articles/donnees-en-france-metropolitaine/chikungunya-dengue-et-zika-donnees-de-la-surveillance-renforcee-en-france-metropolitaine-en-2019)
- 617 [metropolitaine-en-2019](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-transmission-vectorielle/chikungunya/articles/donnees-en-france-metropolitaine/chikungunya-dengue-et-zika-donnees-de-la-surveillance-renforcee-en-france-metropolitaine-en-2019).
- 618 16. Adhami J, Reiter P. Introduction and establishment of *Aedes* (*Stegomyia*) *albopictus* skuse
- 619 (Diptera: Culicidae) in Albania. J Am Mosq Control Assoc. 1998;14(3):340-3.
- 620 17. Sabatini A, Raineri V, Trovato G, Coluzzi M. [*Aedes albopictus* in Italy and possible diffusion of
- 621 the species into the Mediterranean area]. Parassitologia. 1990;32(3):301-4.
- 622 18. Medlock JM, Hansford KM, Versteirt V, Cull B, Kampen H, Fontenille D, et al. An
- 623 entomological review of invasive mosquitoes in Europe. Bull Entomol Res. 2015;105(6):637-63.
- 624 19. Vega-Rua A, Zouache K, Caro V, Diancourt L, Delaunay P, Grandadam M, et al. High efficiency
- 625 of temperate *Aedes albopictus* to transmit chikungunya and dengue viruses in the Southeast of
- 626 France. PLoS One. 2013;8(3):e59716.
- 627 20. Paupy C, Delatte H, Bagny L, Corbel V, Fontenille D. *Aedes albopictus*, an arbovirus vector:
- 628 from the darkness to the light. Microbes and infection / Institut Pasteur. 2009;11(14-15):1177-85.
- 629 21. Metselaar D, Grainger CR, Oei KG, Reynolds DG, Pudney M, Leake CJ, et al. An outbreak of
- 630 type 2 dengue fever in the Seychelles, probably transmitted by *Aedes albopictus* (Skuse). Bulletin of
- 631 the World Health Organization. 1980;58(6):937-43.
- 632 22. Sabin AB. Research on dengue during World War II. The American journal of tropical
- 633 medicine and hygiene. 1952;1(1):30-50.
- 634 23. Coulanges P, Clercy Y, Jousset FX, Rodhain F, Hannoun C. [Dengue at Reunion: isolation of a
- 635 strain at the Pasteur Institute of Madagascar]. Bull Soc Pathol Exot. 1979;72(3):205-9.
- 636 24. Effler PV, Pang L, Kitsutani P, Vorndam V, Nakata M, Ayers T, et al. Dengue fever, Hawaii,
- 637 2001-2002. Emerg Infect Dis. 2005;11(5):742-9.
- 638 25. Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of
- 639 *Aedes albopictus* for dengue virus transmission. PLoS Negl Trop Dis. 2010;4(5):e646.

26. Wang E, Ni H, Xu R, Barret ADT, Watowich SJ, Gubler DJ, et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. *J Virol.* 2000;74(7):3227-34.
27. Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, et al. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. *Science (New York, NY).* 2015;350(6257):217-21.
28. Slonchak A, Hugo LE, Freney ME, Hall-Mendelin S, Amarilla AA, Torres FJ, et al. Zika virus noncoding RNA suppresses apoptosis and is required for virus transmission by mosquitoes. *Nat Commun.* 2020;11(1):2205.
29. Goertz GP, van Bree JWM, Hiralal A, Fernhout BM, Steffens C, Boeren S, et al. Subgenomic flavivirus RNA binds the mosquito DEAD/H-box helicase ME31B and determines Zika virus transmission by *Aedes aegypti*. *Proc Natl Acad Sci U S A.* 2019;116(38):19136-44.
30. Yeh SC, Pompon J. Flaviviruses Produce a Subgenomic Flaviviral RNA That Enhances Mosquito Transmission. *DNA Cell Biol.* 2018;37(3):154-9.
31. Pompon J, Manuel M, Ng GK, Wong B, Shan C, Manokaran G, et al. Dengue subgenomic flaviviral RNA disrupts immunity in mosquito salivary glands to increase virus transmission. *PLoS Pathog.* 2017;13(7):e1006535.
32. Goertz GP, Fros JJ, Miesen P, Vogels CB, van der Bent ML, Geertsema C, et al. Noncoding Subgenomic Flavivirus RNA Is Processed by the Mosquito RNA Interference Machinery and Determines West Nile Virus Transmission by *Culex pipiens* Mosquitoes. *J Virol.* 2016;90(22):10145-59.
33. Filomatori CV, Carballeda JM, Villordo SM, Aguirre S, Pallares HM, Maestre AM, et al. Dengue virus genomic variation associated with mosquito adaptation defines the pattern of viral non-coding RNAs and fitness in human cells. *PLoS Pathog.* 2017;13(3):e1006265.
34. Pallares H, Costa Navarro GS, Villordo S, Merwaiss F, de Borja L, Gonzalez Lopez Ledesma MM, et al. Zika Virus sRNA Generation Requires Cooperativity between Duplicated RNA Structures that Are Essential for Productive Infection in Human Cells. *J Virol.* 2020.
35. Schuffenecker I, Itman I, Michault A, Murri S, Frangeul L, Vaney MC, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. *PLoS Med.* 2006;3(7):e263.
36. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. *PLoS Pathog.* 2007;3(12):e201.
37. Vazeille M, Moutailler S, Coudrier D, Rousseaux C, Khun H, Huerre M, et al. Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, *Aedes albopictus*. *PLoS One.* 2007;2(11):e1168.
38. Roby JA, Pijlman GP, Wilusz J, Khromykh AA. Noncoding subgenomic flavivirus RNA: multiple functions in West Nile virus pathogenesis and modulation of host responses. *Viruses.* 2014;6(2):404-27.
39. Goertz GP, Pijlman GP. Dengue Non-coding RNA: TRIMmed for Transmission. *Cell Host Microbe.* 2015;18(2):133-4.
40. Villordo SM, Filomatori CV, Sanchez-Vargas I, Blair CD, Gamarnik AV. Dengue virus RNA structure specialization facilitates host adaptation. *PLoS Pathog.* 2015;11(1):e1004604.
41. Pijlman GP, Funk A, Kondratieva N, Leung J, Torres S, van der Aa L, et al. A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity. *Cell Host Microbe.* 2008;4(6):579-91.
42. Schuessler A, Funk A, Lazear HM, Cooper DA, Torres S, Daffis S, et al. West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response. *J Virol.* 2012;86(10):5708-18.
43. Vogels CB, van de Peppel LJ, van Vliet AJ, Westenberg M, Ibanez-Justicia A, Stroo A, et al. Winter Activity and Aboveground Hybridization Between the Two Biotypes of the West Nile Virus Vector *Culex pipiens*. *Vector Borne Zoonotic Dis.* 2015;15(10):619-26.
44. Pompon J, Morales-Vargas R, Manuel M, Huat Tan C, Vial T, Hao Tan J, et al. A Zika virus from America is more efficiently transmitted than an Asian virus by *Aedes aegypti* mosquitoes from Asia. *Sci Rep.* 2017;7(1):1215.

45. Chapman EG, Moon SL, Wilusz J, Kieft JS. RNA structures that resist degradation by Xrn1 produce a pathogenic Dengue virus RNA. *Elife*. 2014;3:e01892.
46. Manni M, Guglielmino CR, Scolari F, Vega-Rua A, Failloux AB, Somboon P, et al. Genetic evidence for a worldwide chaotic dispersion pattern of the arbovirus vector, *Aedes albopictus*. *PLoS Negl Trop Dis*. 2017;11(1):e0005332.
47. Sherpa S, Rioux D, Pougnet-Lagarde C, Despres L. Genetic diversity and distribution differ between long-established and recently introduced populations in the invasive mosquito *Aedes albopictus*. *Infect Genet Evol*. 2018;58:145-56.
48. Vasilakis N, Deardorff ER, Kenney JL, Rossi SL, Hanley KA, Weaver SC. Mosquitoes put the brake on arbovirus evolution: experimental evolution reveals slower mutation accumulation in mosquito than vertebrate cells. *PLoS Pathog*. 2009;5(6):e1000467.
49. Stapleford KA, Coffey LL, Lay S, Borderia AV, Duong V, Isakov O, et al. Emergence and transmission of arbovirus evolutionary intermediates with epidemic potential. *Cell Host Microbe*. 2014;15(6):706-16.
50. Funk A, Truong K, Nagasaki T, Torres S, Floden N, Balmori Melian E, et al. RNA structures required for production of subgenomic flavivirus RNA. *J Virol*. 2010;84(21):11407-17.
51. Akiyama BM, Eiler D, Kieft JS. Structured RNAs that evade or confound exonucleases: function follows form. *Curr Opin Struct Biol*. 2016;36:40-7.
52. Chapman EG, Costantino DA, Rabe JL, Moon SL, Wilusz J, Nix JC, et al. The structural basis of pathogenic subgenomic flavivirus RNA (sfRNA) production. *Science*. 2014;344(6181):307-10.
53. Akiyama BM, Laurence HM, Massey AR, Costantino DA, Xie X, Yang Y, et al. Zika virus produces noncoding RNAs using a multi-pseudoknot structure that confounds a cellular exonuclease. *Science*. 2016;354(6316):1148-52.
54. Moon SL, Dodd BJ, Brackney DE, Wilusz CJ, Ebel GD, Wilusz J. Flavivirus sfRNA suppresses antiviral RNA interference in cultured cells and mosquitoes and directly interacts with the RNAi machinery. *Virology*. 2015;485:322-9.
55. Schnettler E, Sterken MG, Leung JY, Metz SW, Geertsema C, Goldbach RW, et al. Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and Mammalian cells. *J Virol*. 2012;86(24):13486-500.
56. Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC, Higgs S. Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to *Aedes albopictus* and *Ae. aegypti* mosquitoes. *PLoS One*. 2009;4(8):e6835.
57. Tsetsarkin KA, Chen R, Sherman MB, Weaver SC. Chikungunya virus: evolution and genetic determinants of emergence. *Curr Opin Virol*. 2011;1(4):310-7.
58. Syenina A, Vijaykrishna D, Gan ES, Tan HC, Choy MM, Siriphanitchakorn T, et al. Positive epistasis between viral polymerase and the 3' untranslated region of its genome reveals the epidemiologic fitness of dengue virus. *Proc Natl Acad Sci U S A*. 2020;117(20):11038-47.
59. Brackney DE, Scott JC, Sagawa F, Woodward JE, Miller NA, Schilkey FD, et al. C6/36 *Aedes albopictus* cells have a dysfunctional antiviral RNA interference response. *PLoS Negl Trop Dis*. 2010;4(10):e856.
60. Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, Failloux AB, et al. Chikungunya virus, southeastern France. *Emerg Infect Dis*. 2011;17(5):910-3.
61. Fansiri T, Fontaine A, Diancourt L, Caro V, Thaisomboonsuk B, Richardson JH, et al. Genetic mapping of specific interactions between *Aedes aegypti* mosquitoes and dengue viruses. *PLoS Genet*. 2013;9(8):e1003621.
62. Christenbury JG, Aw PP, Ong SH, Schreiber MJ, Chow A, Gubler DJ, et al. A method for full genome sequencing of all four serotypes of the dengue virus. *J Virol Methods*. 2010;169(1):202-6.
63. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014;30(15):2114-20.
64. Boisvert S, Raymond F, Godzaridis E, Laviolette F, Corbeil J. Ray Meta: scalable de novo metagenome assembly and profiling. *Genome Biol*. 2012;13(12):R122.
65. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*. 2012;9(4):357-9.

66. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9.
67. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010;26(6):841-2.
68. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. *Nucleic Acids Res*. 2012;40(22):11189-201.
69. Nelson CW, Moncla LH, Hughes AL. SNPGenie: estimating evolutionary parameters to detect natural selection using pooled next-generation sequencing data. *Bioinformatics*. 2015;31(22):3709-11.
70. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res*. 2003;31(13):3406-15.
71. Darty K, Denise A, Ponty Y. VARNA: Interactive drawing and editing of the RNA secondary structure. *Bioinformatics*. 2009;25(15):1974-5.
72. Villordo SM, Carballeda JM, Filomatori CV, Gamarnik AV. RNA Structure Duplications and Flavivirus Host Adaptation. *Trends Microbiol*. 2016;24(4):270-83.
73. Aubry F, Nougairede A, de Fabritus L, Querat G, Gould EA, de Lamballerie X. Single-stranded positive-sense RNA viruses generated in days using infectious subgenomic amplicons. *J Gen Virol*. 2014;95(Pt 11):2462-7.
74. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. *Scandinavian Journal of Statistics*. 1979;6(2):65-70.




Figure 1. Susceptibilities of six European *Ae. albopictus* populations to DENV-1 (1806 and 30A): **a** infection rate, **b** dissemination efficiency and **c** viral titers in heads. Adult female mosquitoes were challenged with DENV-1 from France (1806) and Thailand (30A) at a titer of 10^7 FFU/mL. At 14 and 21 dpi, mosquitoes were sacrificed and decapitated. Bodies and heads were homogenized and titrated on C6/36 cells. Infection rates were determined using positive/negative scoring (i.e. without estimating the number of viral particles), while viral titers at sites of dissemination were quantified *via* focus-forming assay. The error bars correspond to the confidence intervals (95%) (**a**, **b**), and the bar to the mean (**c**). In brackets is indicated the sample size.




Figure 2. Experimental design for DENV-1 adaptation to *Ae. albopictus*. The parental strains 1806 (France) and 30A (Thailand) were passaged 10 times on a single *Ae. albopictus* population from Nice, France. Each passage includes: mosquito infectious blood-meal with DENV-1, collection of mosquito saliva at day 21 post-infection, viral amplification of saliva on *Ae. albopictus* cell cultures for 8 days, and initiation of the next passage using the viral suspension obtained. Control isolates were serially passaged 10 times on C6/36 cells. Two replicates R1 and R2 were performed.




Figure 3. Frequency variation and genomic position of consensus level-reaching variants during passages. **a** The top panels correspond to DENV-1 passaged on C6/36 cells as controls and the bottom panels to DENV-1 passaged on *Ae. albopictus* mosquitoes. Bold lines represent the variant 10,418 in the 3'UTR. **b** Variants are represented with a colored segment according to the mutation type (non-coding: black; non-synonymous: red; synonymous: blue). The position of the only shared variant between two replicates is highlighted in yellow.




Figure 4. Infection, Dissemination and Transmission of DENV-1 (Parental, P10_R1, and P10_R2) by *Ae. aegypti* Pazar and *Ae. albopictus* Nice. Mosquitoes were exposed to blood meals at a titer of 10^7 FFU/mL. Females were examined at 7, 14 and 21 dpi. Mosquito body (thorax and abdomen) and head were processed individually to determine (a, b) the infection rate (IR, proportion of mosquitoes with infected body among the engorged mosquitoes) and (c, d) the dissemination efficiency (DE, proportion of mosquitoes with infected head among tested mosquitoes). (e, f) Saliva was collected from individual females to determine the transmission efficiency (TE, proportion of mosquitoes with infectious saliva among tested mosquitoes). The Parental strain corresponds to DENV-1 1806, and P10_R1 and P10_R2 refer, respectively, to replicate 1 and replicate 2 of the 10th *in vivo* passages of DENV-1 1806 on *Ae. albopictus*. Asterisks refer to a significant difference ($***p < 10^{-3}$). In brackets, the number of mosquitoes tested. The error bars correspond to the confidence intervals (95%).




Figure 5. Growth curves of the two passages 10 of DENV-1 1806 strain in two cell lines, (a) *Ae. albopictus* C6/36 cells, (b) *Ae. albopictus* U4.4 cells, and (c) human foreskin fibroblasts HFF cells. Cells were infected with the parental strain and the two replicates of the 10th passages of DENV-1 1806 (P10_R1 and P10_R2) at a MOI of 0.1. Supernatants were collected at 4, 6, 8, 10, 24, 48 and 72 hrs post-inoculation. The number of infectious viral particles was determined by focus fluorescent assay on *Ae. albopictus* C6/36 cells. Three replicates were performed for each cell-virus pairing. Error bars show standard deviations.




Figure 6. Analysis of mutation frequencies in the DENV-1 3'UTR. **a** Schematic overview of the DENV-1 3'UTR secondary RNA structure, indicating from 5' to 3' the stem loop (SL)-I, SL-II, dumbbell (DB)-1, DB-2 and 3'SL RNA structures. Single nucleotide variants with a frequency ≥ 0.05 after 10 passages of DENV-1 1806 or 30A in either C6/36 or mosquitoes are highlighted in red. Pseudoknots and other tertiary RNA interactions are indicated by the black lines. **b** Analysis of the mutation frequencies in SL-II and the 3'SL of the parental DENV-1 30A and 1806 sequences, and passages P10 (1806) and P10 (30A). The mutation frequency is indicated by color on a scale from 0 (white) to 1 (red).




Figure 7. Northern blot detection of sfRNA production after C6/36 cells infection with DENV-1 1806. **a** Visualization of sfRNA. 5µg of total RNA from the parental and the two replicates P10_R1 and P10_R2 of DENV-1 1806 or non-infected cells (N) was size separated on a 6% Polyacrylamide/Urea gel. One gel was run for the R1 samples (left) and one for the R2 samples (right), including the negative and parental samples on each gel. Then, RNAs were blotted onto Hybond-N paper and subjected to northern-blotting with a DENV-1 3'UTR specific probe. The bands shown correspond to the DENV genomic RNA (gRNA) and subgenomic flavivirus RNA (sfRNA). As loading control, the ribosomal RNA (rRNA) from the EtBr stained gel are shown. **b** Quantification of the ratio of sfRNA to gRNA production. Band intensities were determined using the 'Measure' function in ImageJ. The intensity of the background (lane N) was subtracted from the readings before the ratio sfRNA/gRNA was calculated by dividing the intensity of the sfRNA by the intensity of the gRNA band for each sample, and then normalized to the average ratio of the parental samples. The statistics were performed using a two-tailed unpaired t-test.




Figure 8. Reverse genetic constructs with the 10,418 mutation do not show higher transmission in *Ae. albopictus*. **a** Transmission of reverse genetic constructs (Parental construct, P10 construct 1, P10 construct 2) by *Ae. albopictus* Nice with reference to Parental and P10 strains. Twenty-one days after an infectious blood meal at a titer of 10^7 FFU/mL, mosquitoes were processed for saliva collection to determine the transmission efficiency (TE, proportion of mosquitoes with infectious saliva among tested mosquitoes). **b** Viral loads in saliva were estimated by focus fluorescent assay on *Ae. albopictus* C6/36 cells. **c, d** A second replicate using the P10 construct 1 was performed. Bars indicate the mean.

Table 1. Details on mosquito populations used for experimental infections with DENV-1.

Species	Mosquito population	Country	Date of collection	Generation used for mosquito infections
<i>Aedes albopictus</i>	Nice	France	August 2011	F3, F11
	Saint-Raphaël	France	November 2012	F3
	Alessandria	Italy	November 2012	F1
	Genoa	Italy	October 2012	F2
	Cornella	Spain	July 2012	F2
	Martorell	Spain	July 2012	F2
<i>Aedes aegypti</i>	Pazar	Turkey	2016	F4

Table S1. Comparisons of infection rates and dissemination efficiencies between mosquitoes infected with two DENV-1 strains (1806 and 30A) and examined at different days post-infection (14 and 21).

Mosquito population	Day post-infection	Fisher's exact test	
		Infection rate	Dissemination efficiency
Alessandria	14	0.093	0.905
	21	0.556	0.479
Genoa	14	0.077	0.022
	21	0.035	0.376
Cornella	14	0.979	0.168
	21	0.808	0.715
Martorell	14	0.496	0.001
	21	0.006	0.002
Nice	14	0.191	0.929
	21	0.371	0.463
Saint-Raphael	14	0.18	0.114
	21	0.334	0.334

Table S2. Comparisons of infection rates and dissemination efficiencies between the 6 mosquito populations infected with a DENV-1 strain (1806 or 30A) and examined at a given day post-infection (14 or 21).

DENV-1	Day post-infection	Fisher's exact test	
		Infection rate	Dissemination efficiency
1806	14	0.0001	0.0001
	21	0.001	0.0001
30A	14	0.0001	0.0001
	21	0.0001	0.0001

Table S3. Comparisons of viral loads in mosquito heads between mosquitoes infected with two DENV-1 strains (1806 and 30A) and examined at different days post-infection (14 and 21).

Mosquito population	Day post-infection	Wilcoxon Rank-Sum test
Alessandria	14	0.292
	21	0.746
Genoa	14	0.533
	21	0.836
Cornella	14	0.439
	21	0.018
Martorell	14	0.073
	21	0.304
Nice	14	0.183
	21	0.857
Saint-Raphael	14	0.032
	21	0.169

Table S4. Position and estimated frequency of SNVs reaching consensus level detected in the mosquito-passaged samples.

Virus	Passage	Replicate	SNV position on DENV genome	Reference nucleotide	SNV	Sequencing depth at position	SNV frequency	Position in codon	Mutation type
1806	2	2	5667	T	C	14231	0.686319	2	No n-synonymous
1806	4	1	4606	A	G	7484	0.953234	3	Synonymous
1806	4	1	7360	T	C	5336	0.962331	3	Synonymous
1806	4	1	10418	T	C	3703	0.94734	NA	no n-coding
1806	4	2	9067	T	C	3998	0.815408	3	Synonymous
1806	5	1	4606	A	G	141288	0.999023	3	Synonymous
1806	5	1	7360	T	C	292005	0.999017	3	Synonymous
1806	5	1	10418	T	C	199563	0.998943	NA	no n-coding
1806	5	2	9067	T	C	94413	0.998856	3	Synonymous
1806	6	1	4606	A	G	37980	0.996288	3	Synonymous
1806	6	1	7360	T	C	20048	0.996758	3	Synonymous
1806	6	1	10418	T	C	18264	0.996605	NA	no n-coding
1806	6	2	9067	T	C	21252	0.996518	3	Synonymous
1806	7	1	3757	C	T	16059	0.55869	3	Synonymous
1806	7	1	4606	A	G	24880	0.996383	3	Synonymous
1806	7	1	7360	T	C	15019	0.997004	3	Synonymous
1806	7	1	10418	T	C	9195	0.996194	NA	no n-coding
1806	7	2	9067	T	C	5095	0.995682	3	Synonymous
1806	8	1	2719	A	G	7900	0.553544	3	Synonymous
1806	8	1	3001	C	T	8388	0.510968	3	Synonymous
1806	8	1	3757	C	T	9649	0.643694	3	Synonymous
1806	8	1	4552	G	A	10485	0.623176	3	Synonymous
1806	8	1	4606	A	G	11782	0.996605	3	Synonymous
1806	8	1	7360	T	C	10285	0.996889	3	Synonymous
1806	8	1	10418	T	C	6829	0.997218	NA	no n-coding
1806	8	2	9067	T	C	4272	0.994616	3	Synonymous
1806	8	2	10418	T	C	3477	0.540696	NA	no n-coding
1806	9	1	1840	C	T	16264	0.545315	3	Synonymous
1806	9	1	2719	A	G	14188	0.790668	3	Synonymous
1806	9	1	3001	C	T	12951	0.792448	3	Synonymous
1806	9	1	3757	C	T	15968	0.830348	3	Synonymous
1806	9	1	4552	G	A	15493	0.828632	3	Synonymous
1806	9	1	4606	A	G	17632	0.996257	3	Synonymous
1806	9	1	7360	T	C	15973	0.997308	3	Synonymous
1806	9	1	10418	T	C	10027	0.995412	NA	no n-coding
1806	9	2	9067	T	C	6528	0.996477	3	Synonymous
1806	9	2	10418	T	C	5922	0.761905	NA	no n-coding
1806	10	1	2719	A	G	84568	0.877956	3	Synonymous
1806	10	1	3001	C	T	72183	0.972334	3	Synonymous
1806	10	1	3757	C	T	92700	0.975955	3	Synonymous
1806	10	1	4552	G	A	101912	0.974851	3	Synonymous
1806	10	1	4606	A	G	101144	0.9991	3	Synonymous
1806	10	1	7360	T	C	213796	0.998948	3	Synonymous
1806	10	1	10418	T	C	141416	0.998883	NA	no n-coding
1806	10	2	9067	T	C	29741	0.998352	3	Synonymous
1806	10	2	10418	T	C	37209	0.995996	NA	no n-coding
30A	5	1	1768	T	A	312358	0.787503	3	Synonymous
30A	6	1	1768	T	A	1264	0.665348	3	Synonymous
30A	7	1	1768	T	A	8290	0.563209	3	Synonymous
30A	7	2	1611	C	T	8758	0.704042	2	No n-synonymous
30A	7	2	2977	T	C	9778	0.710268	3	Synonymous
30A	7	2	3442	G	A	5856	0.691257	3	Synonymous
30A	7	2	10208	C	T	5068	0.608327	1	Synonymous
30A	8	1	448	T	C	1075	0.6	3	Synonymous
30A	8	1	1768	T	A	2389	0.821683	3	Synonymous
30A	8	1	1959	A	G	2247	0.604806	2	No n-synonymous
30A	8	1	5822	C	T	1181	0.519898	1	Synonymous
30A	8	1	8149	T	C	1248	0.615385	3	Synonymous
30A	8	1	10258	A	T	1017	0.612586	3	No n-synonymous
30A	8	2	1611	C	T	5281	0.937512	2	No n-synonymous
30A	8	2	2977	T	C	5192	0.943374	3	Synonymous
30A	8	2	3442	G	A	3062	0.931417	3	Synonymous
30A	8	2	10208	C	T	1783	0.902973	1	Synonymous
30A	9	1	694	C	T	1501	0.774151	3	Synonymous
30A	9	1	2002	C	T	2058	0.757532	3	Synonymous
30A	9	1	6658	G	A	1778	0.72216	3	Synonymous
30A	9	1	6728	C	T	2246	0.769813	1	Synonymous
30A	9	1	7267	C	T	978	0.747444	3	Synonymous
30A	9	1	9504	A	G	1527	0.762279	2	No n-synonymous
30A	9	2	1611	C	T	11211	0.997681	2	No n-synonymous
30A	9	2	2716	A	G	5452	0.762656	3	Synonymous
30A	9	2	2977	T	C	11160	0.996416	3	Synonymous
30A	9	2	3442	G	A	7394	0.994725	3	Synonymous
30A	9	2	7952	T	C	11955	0.931409	1	No n-synonymous
30A	9	2	8485	T	C	13405	0.898396	3	Synonymous
30A	9	2	10208	C	T	5542	0.997835	1	Synonymous
30A	10	1	694	C	T	19924	0.984039	3	Synonymous
30A	10	1	2002	C	T	35756	0.984758	3	Synonymous
30A	10	1	2200	T	C	20712	0.876014	3	Synonymous
30A	10	1	6658	G	A	18057	0.976574	3	Synonymous
30A	10	1	6728	C	T	23549	0.982717	1	Synonymous
30A	10	1	7267	C	T	17245	0.985503	3	Synonymous
30A	10	1	9504	A	G	22552	0.982973	2	No n-synonymous
30A	10	2	1611	C	T	18775	0.998189	2	No n-synonymous
30A	10	2	2716	A	G	13145	0.909623	3	Synonymous
30A	10	2	2977	T	C	13526	0.998743	3	Synonymous
30A	10	2	3442	G	A	8885	0.996511	3	Synonymous
30A	10	2	7952	T	C	10940	0.999177	1	No n-synonymous
30A	10	2	8485	T	C	7629	0.994626	3	Synonymous
30A	10	2	10208	C	T	13546	0.99904	1	Synonymous

Table S5. Sequences of the three reverse genetic constructs (Parental, P10 construct 1, P10 construct 2) using the deep sequencing method described in materials and methods. Only substitutions with a mutation frequency > 5% were considered significant for further analysis. The parental strain P0 was used as the reference sequence. The two P10 constructs presented the mutation 10,418 (in grey) at a frequency close to 100% beside other mutations.

Clone	Mutation	Position	Frequency (%)	AA Position	AA change	Gene
Parental IC	A->G	211	27.2	39	Ser	Capsid
	T->C	4697	25.9	60	Tyr -> His	nsp3
	C->T	8650	30	359	Asp	nsp5
	T->C	9172	6.3	533	Asp	nsp5
P10 IC1	T->C	1513	5	193	Phe	Env
	G->T	2684	5.4	89	Val -> Phe	nsp1
	T->C	3472	5.3	351	Ser	nsp1
	A->T	3581	5.6	36	Thr -> Ser	nsp2a
	T->C	5173	52.5	218	Arg	nsp3
	G->A	5764	5.8	415	Gly	nsp3
	C->A	6346	5.5	609	Arg	nsp3
	A->G	7210	33.1	128	Ala	nsp4b
P10 IC2	T->C	10418	100			
	T->C	7321	98.8	165	Phe	nsp4b
	G->A	9571	98.4	666	Val	nsp5
	T->C	10418	99.9			

Table S6. Primers used to generate subgenomic DNA fragments (ISA procedure)

pCMV_F	TCAATATTGGCCATTAGCCATATTAT	pCMV tagged
pCMV_tag_R	GTTCTTGTCGGTCCACGTAGACTAACAACCTCGGTTCACTAAACGAGCTCTGC	
1806_I_tag_F	CTATATAAGCAGAGCTCGTTTAGTGAACCGAGTTGTTAGTCTACGTGGACCGA	Fragment I tagged
1806_I_R	CTGACCCTGCAGAGACCATTGA	
1806_II_F	CCACAACAGTCACAGGAAAGATA	Fragment II
1806_II_R	CTCCACGTCCATGTTCTCCTC	
1806_III_F	CAGCAATAGACGGGGAGTACAG	Fragment III WT
1806_III_WT_R	CTCAATCCGTGGCTTTCGGC	
1806_III_F	CAGCAATAGACGGGGAGTACAG	Fragment III Mut
1806_III_Mut_R	CTCAGTCCGTGGCTTTCGGC	
<u>3UTRHDRSV40_F</u>	GTGAGCCCCGTCCAAGGACGT	<u>367 nts of 3'UTR + HDR/SV40pA (WT and Mut)</u>
<u>3UTRHDRSV40_R</u>	CTCAGGGTCAATGCCAGCGCT	

Figure S1. Viral titers of cell culture supernatants used to run passages in the experimental selection for DENV-1 adaptation to *Ae. albopictus*. Saliva were collected from 15-25 mosquitoes 19-21 days after infection and pooled to inoculate a monolayer of C6/36 *Ae. albopictus* cells. After 8 days at 28°C, cell culture supernatants were collected and provided to mosquitoes to run the next passage. Ten passages were performed. The supernatants were titrated by focus fluorescent assay on *Ae. albopictus* C6/36 cells. Viral titer was expressed in FFU/mL. Two biological replicates were performed for each viral strain, DENV-1 30A and DENV-1 1806.





Figure S2. Sequencing coverage and depth by sample.



Supplemental Text. Sequences of the *de novo* subgenomic DNA fragments used during the ISA procedure

pCMV

GAATAAGGGCGACACGGAAATGTCACCCAACCTGATCTTCAGCATCTTCAATATTGGCCATTAGCCAT
ATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCA
TAATATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGGCATTGATTATTGACTAGTTA
TTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTA
CGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATGACGTCAATAATGACGTATGTT
CCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCA
CTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGC
CCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTTCTACTTGGCAGTACATCTACGTATTA
GTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTC
ACGGGGATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGG
ACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAATGGGCGGTAGGCGTGTACGGTGGGA
GGTCTATATAAGCAGAGCTCGTTTAGTGAACCG

367 last nucleotides of 3'UTR + HDR/SV40pA (WT; T)

GTGAGCCCCGTCCAAGGACGTAAAATGAAGTCAGGCCGAAAGCCACGGATTGAGCAAGCCGTGCTG
CCTGTGGCTCCATCGTGGGGATGTAAAAACCCGGGAGGCTGCAACCCATGGAAGCTGTACGCATGGG
GTAGCAGACTAGTGGTTAGAGGAGACCCCTCCCTAGACATAACGCAGCAGCGGGGGCCCAACACCAG
GGGAAGCTGTACCTTGGTGGTAAGGACTAGAGGTTAGAGGAGACCCCCGCACAACAACAAACAGC
ATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCATCATTCCAGGCACAGAACGCCA
GAAAATGGAATGGTGCTGTTGAATCAACAGGTTCTGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGC
CGGCTGGGCAACATTCCGAGGGGACCGTCCCCTCGGTAATGGCGAATGGGACTCGCGACAGACATGA
TAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAAATGCTTTATTTGTGA
AATTAAGCGCTGGCATTGACCCTGAGGTTTACCCTCACAAACGTTCCAGT

367 last nucleotides of 3'UTR + HDR/SV40pA (Mutant; C)

GTGAGCCCCGTCCAAGGACGTAAAATGAAGTCAGGCCGAAAGCCACGGACTGAGCAAGCCGTGCTG
CCTGTGGCTCCATCGTGGGGATGTAAAAACCCGGGAGGCTGCAACCCATGGAAGCTGTACGCATGGG
GTAGCAGACTAGTGGTTAGAGGAGACCCCTCCCTAGACATAACGCAGCAGCGGGGGCCCAACACCAG
GGGAAGCTGTACCTTGGTGGTAAGGACTAGAGGTTAGAGGAGACCCCCGCACAACAACAAACAGC
ATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCATCATTCCAGGCACAGAACGCCA
GAAAATGGAATGGTGCTGTTGAATCAACAGGTTCTGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGC
CGGCTGGGCAACATTCCGAGGGGACCGTCCCCTCGGTAATGGCGAATGGGACTCGCGACAGACATGA
TAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAAATGCTTTATTTGTGA
AATTAAGCGCTGGCATTGACCCTGAGGTTTACCCTCACAAACGTTCCAGT